Oric Pharmaceuticals, Inc. short interest in 2026
In 2026, Oric Pharmaceuticals, Inc.'s disclosed short interest ran from 21.70% of shares outstanding on 15 Jan 2026 to 16.91% on 15 Sep 2026, a change of -4.79 percentage points. The year's high was 22.23% on 30 Jan 2026 and its low 16.66% on 31 Aug 2026, averaging 20.42% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 19.13 days on 13 Feb 2026. Full history: Oric Pharmaceuticals, Inc..
Cite this page
By year: 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2026 in figures
- Start of year
- 21.70% (15 Jan 2026)
- End of year
- 16.91% (15 Sep 2026)
- Change
- -4.79 pp
- High
- 22.23% (30 Jan 2026)
- Low
- 16.66% (31 Aug 2026)
- Average
- 20.42%
- Highest days to cover
- 19.13 (13 Feb 2026)
- SEC filings marked
- 6
Every report in 2026
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2026 | 21.70% | 10.80 | |
| 30 Jan 2026 | 22.23% | 12.79 | |
| 13 Feb 2026 | 22.02% | 19.13 | |
| 27 Feb 2026 | 21.72% | 13.02 | 10-K filed, results (8-K) |
| 13 Mar 2026 | 20.58% | 12.04 | |
| 31 Mar 2026 | 19.28% | 12.86 | |
| 15 Apr 2026 | 20.67% | 5.68 | |
| 30 Apr 2026 | 21.26% | 16.60 | |
| 15 May 2026 | 21.20% | 15.39 | 10-Q filed, results (8-K) |
| 29 May 2026 | 21.19% | 17.24 | |
| 15 Jun 2026 | 20.34% | 10.31 | |
| 30 Jun 2026 | 21.36% | 12.32 | |
| 15 Jul 2026 | 21.30% | 13.53 | |
| 31 Jul 2026 | 21.04% | 13.55 | |
| 14 Aug 2026 | 17.74% | 10.96 | 10-Q filed, results (8-K) |
| 31 Aug 2026 | 16.66% | 16.16 | |
| 15 Sep 2026 | 16.91% | 14.21 |
See also: Oric Pharmaceuticals, Inc.'s full history · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.